Therapeutic plasmapheresis in a complex treatment of patients with chronic hepatitis by Любчак, Владислав Вiкторович et al.
1454
Wiadomości Lekarskie, VOLUME LXXIII, ISSUE 7, JULY 2020 © Aluna Publishing
INTRODUCTION
Chronic diffuse liver diseases (CDLD) remain one of the 
most urgent problems of the present, as they were before, due 
to their widespread prevalence, pathogenetic mechanisms, 
which are not fully studied, unresolved problems of treatment, 
prevention and unfavorable prognosis. The majority of liver 
diseases treated by therapeutists are chronic hepatitis. This is 
a group of diseases caused by various reasons, characterized 
by focal hepatocellular necrosis of varying duration and 
chronic inflammation. The concept of “chronic hepatitis” is 
determined by the disease duration, the conditional limit is 
6 months [1, 2].  Four types of chronic hepatitis are distin-
guished: viral, autoimmune, drug-induced and cryptogenic. 
For today, hepatologists identify the fifth type of the disease 
as alcoholic chronic hepatitis [3,4]. Chronic viral hepatitis is 
more often caused by hepatitis B (HBV), C (HCV) and D 
(HDV) viruses, the last one is usually coincided with hepatitis 
B. High infection rate with the HBV virus of the planet’s 
population is related to its extraordinary prevalence rate and 
resistance, which is 50-100 times higher than that for HIV [5]. 
An important place among hepatitis is drug-induced, caused 
by hepatotoxic drugs[6].
Medicinal liver damage is reason for approximately 2% of 
liver jaundices. At present, there are known more than 1,000 
drugs that can cause drug-induced hepatitis. Liver lesions are 
more common in enteral use of drugs, due to the peculiarities 
of their metabolism and blood supply of hepatic tissue [7,8]. 
Depending on the influence of the etiological factor, the 
synthetic activity of the liver is reduced, the detoxication 
function suffers and the regulation of metabolic processes 
is violated. The imbalance between the physiological needs 
and the functional capabilities of the damaged liver leads 
to the development of complications [9]. 
In this regard, the problem of finding additional therapeu-
tic measures, including the development and introduction 
of new methods of pathogenetic therapy remains relevant. 
There are publications about the successful use of the 
apheresis method in modern literature. The following types 
of apheresis are distinguished: sorption, cypress, high-vol-
ume/massive plasma exchange (HVP), immunosorbtion 
(IS), apheresis LDL, plasmapheresis. Plasmapheresis is a 
method of efferent therapy in which the patient or donor’s 
blood is passed through a medical device that separates 
the plasma from other components of the blood. Plasma is 
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ABSTRACT
The aim: To determine the pathogenetic expediency, efficiency and the place of therapeutic plasmapheresis in a complex treatment of patients with chronic hepatitis.
Materials and methods: It was carried out the analysis of case histories of 77 patients. In the course of treatment, the patients were diagnosed with chronic toxic hepatitis 
(K.71). Diagnosis was exposed in accordance with the official documentation introduced by the Gastroenterological department of Sumy Regional Clinical Hospital CH”SRCH”, 
Sumy Regional Infectious Diseases Clinical Hospital named after Krasovytsky ZY and Sumy Regional Center of Blood Service.
Results: It was found that total protein indicator is the normal range and albumin after plasmapheresis and during conservative treatment.
Markers of cytolysis and cholestasis are have great value may. The most significant changes were observed in rates indicating lesion of the hepatic parenchyma, including ALT, 
AsAT and alkaline phosphatase. In conservative treatment, the percentage of the alkaline phosphatase level improved by 31%, after the course of plasmapheresis – by 58%. The 
obtained figures of cholestasis indexes indicate the effectiveness of both methods of treatment, but treatment with plasmapheresis has a more expressed effect on the decrease 
of alkaline phosphatase level. The level of bilirubin improve on 38,8% after plasmapheresis and 65% in the comparison group.
Conclusion: Inclusion in the complex therapy of chronic hepatitis plasmapheresis reduces the severity of cytolysis and cholestasis, increases remission and significantly improves 
clinical manifestations. 
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removed and replaced by a plasma replacement solution 
(for example: albumin, NaCl 0.9%, donor plasma) [10]. 
It is important the type of solution that should be used in 
the process of therapeutic apheresis for a practitioner, as 
well as the state of the factors of blood coagulation, since 
there is a risk of exhaustion of coagulation factors, espe-
cially after weekly PF and the timing of the procedure. 
There are two main methods of automatic plasmapheresis: 
centrifugal and filtration. The first method is carried out 
by centrifugation of blood with a constant or intermittent 
flow of it in special devices, the other one is based on blood 
filtration in special plasma filters [11]. 
THE AIM 
The aim of our research is to determine the pathogenetic 
expediency, efficiency and place of therapeutic plasma-
pheresis in the complex treatment of patients with chronic 
hepatitis.
Objectives of the study: 1. To establish the validity of 
conservative treatment effect and treatment effect with the 
addition of plasmapheresis on hematological parameters 
after 2 weeks.
2. To determine the economic effect of the inclusion of 
plasmapheresis in therapy.
MATERIALS AND METHODS
The research was conducted by the Department of Public 
Health in the Medical Institute of Sumy State University. 
The analysis of the case histories was carried out on 77 
patients (43 men and 34 women) aged from 15 to 75 years. 
In the process of treatment, patients were diagnosed with 
chronic toxic hepatitis (K.71). Diagnosis of patients was 
exhibited according to the official documentation by the 
implemented Gastroenterological department of Sumy 
Regional Clinical Hospital “SRCH”, Sumy Regional In-
fectious Diseases Clinical Hospital named by Krasovytskyi 
Z.Y. and Sumy Regional Blood Service Center according 
to the ICD-10.
All patients were divided into two representative groups 
with the only conservative drug therapy (n = 39) and 
conservative treatment with therapeutic plasmapheresis 
(n = 38).
A conservative therapy of hepatitis included a diet lim-
itation of protein in the food; correction of hemostasis, 
hypoalbuminemia and water electrolyte state; infusion-de-
toxification therapy; prevention of erosive-ulcerous lesions 
of the gastrointestinal tract; conducting a medical therapy 
aimed at reducing liver encephalopathy.
In this case, a device for membrane plasmapheresis 
AMPA-TT (trademark “Hemofenix”) was used, with the 
complex of a plasma filter PFM-TT “ROSA” and blood-
flow lines. The process of membrane plasmapheresis on 
the device “Hemofenix” is carried out according to a 
single-needle scheme in a sterile extracorporeal contour 
of a single use. Vascular access was performed through 
peripheral subcutaneous veins (elbow vein). Average 
duration of the procedure is 1-hour ± 10minutes. During 
the procedure, an average of 650 ± 30 ml of plasma was 
obtained. During the operation, the patient was given 
NACl 0.9% – 200 ml, rheosorbilact – 200 ml, glucagon 
– 250 ml, heparin – 10% OD. In some patients instead of 
sorbilact/rheosorbilact were used rheopolyglucinum – 200 
ml or refortanum – 200 ml. In total, for treatment, there 
were received an average of 3370 ml. of plasma (about 1 
volume of circulating blood). The number of procedures 
for therapeutic plasmapheresis, the maximum number of 
performed aperitifs is eight, the minimum are 3 times at 
intervals between procedures for 2 days. To control the 
parameters of homeostasis, a complex of clinical and 
instrumental-laboratory methods was used. Among the 
clinical methods, the following parameters were assessed: 
general condition, skin color, blood pressure, pulse and 
body temperature, which were performed for all patients 
before, during and after the method of extracorporeal 
hemocorrection. Among instrumental and laboratory meth-
ods: mesenchymal inflammation (total protein, albumin), 
cytolysis markers (ALT, AsAT) and cholestasis (activity of 
alkaline phosphatase, bilirubin) were studied. Blood sam-
ples for laboratory control of the studied parameters were 
taken during the admission of the patient in the hospital 
(before treatment) during a conservative therapy and after 
the application of the course of therapeutic plasmapheresis.
Albumin index was determined by electrophoresis on 
cellulose acetate tapes. 
Alanine aminotransferase (ALT) was determined by the 
kinetic method of the automatic analyzer Sobas C311 using 
the test system: AST, Roche Diagnostics.
Aspartate aminotransferase (AsAT) was determined by 
the kinetic method of the automatic analyzer Sobas C311 
using the test system: AST, Roche Diagnostics.
Rates of alkaline phosphatase were calculated by the 
colorimetric method of the Sobas C311 analyzer using the 
test system: ALP2 Roche Diagnostics.
The level of total bilirubin was determined by the En-
drassic-Klegorn-Grof method.
The study was conducted in accordance with the re-
quirements of medical statistics, on the condition of the 
informed voluntary consent of patients for the processing 
of personal data. The resulting digital information was 
processed with using Microsoft Excel 2010, Statistica 10 
(StatSoft Inc. USA) software using descriptive, compar-
ative analysis.
The general statistical analysis of determining the authen-
ticity of the difference in quantitative characteristics between 
the samples was used by Student’s criterion. Differences 
were considered statistically significant at p <0.05.
RESULTS AND DISCUSSION
According to the results of the monitoring of patients with 
CH, changes in clinical and laboratory parameters were 
established. After analyzing 77 stories of the disease, the 
following distribution of patients was found: 34 (44%) 
women and 43 (56%) men.
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According to the age, all patients were divided into the 
following groups: from 15 to 25 years old – 9 (12%), from 
26 to 35 years old – 14 (18%), from 36 to 45 years old – 19 
(25%), from 46 to 55 years old – 21 (27%), from 56 to 65 
years old – 10 (13%), from 66 to 75 years old – 4 (5%).
According to the results of the monitoring patients, there 
were diagnosed the leading clinical syndromes, the most 
marked were astenovegetative and dyspeptic. Also among 
patients were found hepatomegaly (enlargement of the 
liver for 6-8cm), yellowness of the skin and itchy skin. By 
evaluating the laboratory rates, changes in mesenchymal 
inflammation, markers of cytolysis and cholestasis were 
determined by us.
A rank evaluation of the degree of accuracy (according 
to the t-criterion) of all studied rates of homeostasis in the 
patients under the influence of treatment plasmapheresis 
and a conservative treatment showed that membrane 
plasmapheresis with the conservative method, had a more 
marked effect on homeostatic functions. These studies in 
groups are presented in Table I.
Analysis of the data obtained during the work showed 
that comparing the results of biochemical studies in 
classical therapy and therapy using plasmapheresis, 
the greatest effect was observed precisely when using 
plasmapheresis.
In the course of scientific work, were determined chang-
es biochemical parameters. It was found that the level of 
total protein on the background of the plasmapheresis 
procedure (before the procedure – 73,6 ± 5,2 g/l (p <0,05), 
after – 68,9 ± 5,1 g/l (p <0,05)) and during conservative 
treatment (before treatment initiation – 76.4 ± 8.8 g /l (p 
<0.05), after treatment – 72.4 ± 6.1 g /l (p<0.05)) has not 
changed significantly and is within the normal range, indi-
cating the same effect of conservative and plasmapheresis 
treatment on this indicator. It should be noted that in the 
first day was determined a significant decrease in total 
protein after plasmapheresis, but after 2 weeks the figure 
returned to normal.
Albumin after 2 weeks of treatment did not change sta-
tistically, this indicates that the effect of plasmapheresis 
on this indicator during the specified period is unreliable.
The most significant changes were observed in rates in-
dicating lesion of the hepatic parenchyma, including ALT, 
AsAT and alkaline phosphatase. During a conservative 
Fig 1. Sexual distribution of persons
Fig 2. Age distribution of patients
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treatment, the AsAT rates were: till 90,7 ± 20,1 O/L against 
40,1 ± 15,1 O/L, in the percentage the indicator changed 
by 29%. During therapeutic plasmapheresis: before the 
procedure was 125,6 ± 41,2 O/L, against 37,1 ± 14,2 O/L, 
the percentage changed by 70%. 
Indicators of ALT to a conservative treatment were 76,7 
± 20,2 O/L, against  40,2 ± 12,0 O/L, the normalization 
of the indicator is 48%. In the course of therapeutic plas-
mapheresis: till 94,2 ± 23,4 O/L, against 38,3 ± 15,1 O/L 
the rate changed by 59%. The obtained figures points out 
the effectiveness of both methods of treatment, but plas-
mapheresis has more expressed effect on the decrease of 
cytolysis markers. 
Having evaluated the level of alkaline phosphatase in 
the main group and the comparison one, it was before 
the procedure 152.0 ± 19.1 O/L, after 105.5 ± 20.3 O/L, 
in contrast to the control group (before 174.9 ± 41.8 O/L, 
after was 73.1 ± 27.4 O/L). In conservative treatment, the 
percentage improved by 31%, after the course of plasma-
pheresis – by 58%. 
Further research of cholestasis indexes points out 
changes in the level of total bilirubin. Normally, it is 3.4-
20.5 mcmol/L. There is a deviation from these normative 
figures in both groups. In the main group before of plas-
mapheresis procedures, it is 74.1 ± 21.4 mcmol/L, against 
25.5 ± 8.1 mcmol/L, the index has changed by 66%. In 
the comparison group: before is 67.2 ± 10.0 mcmol/L, 
after – 41.1 ± 8.1 mcmol/L, the improvement is by 39%. 
The obtained figures indicate the effectiveness of both 
methods of treatment, but treatment with plasmapheresis 
has a more expressed effect on the decrease of alkaline 
phosphatase level.
DISCUSSION
The analysis of the database showed that the conservative 
therapy led to the improvement in the patient’s condition 
less than after plasmapheresis. The synthetic function of 
the liver was recollected more slowly. The level of total 
protein, albumin remained within the norm in 2 weeks.
Patients in the group with therapeutic plasmapheresis were 
performed, showed the improvement in the general condition: 
faster asteno-vegetative and dyspeptic syndromes, decreasing of 
skin itching and intoxication symptoms. After courses of plas-
mapheresis at intervals of 2 days, there was a significant decrease 
in AsAT, ALT, AP and total bilirubin, which was maintained 2 
weeks after the completion of the procedures. Due to the ade-
quate replacement of single-group plasma losses, the patients are 
registered with the improvement in albumin and total protein 
rates, although they were also within normal parameters. Thus, 
complex treatment of CH with the inclusion of plasmapheresis 
has a positive effect on the disease due to the mechanical removal 
of toxic products from the blood of patients.
The statistical data processing demonstrates a more 
valid treatment effect on hematological parameters when 
plasmapheresis is included in the course of therapy. Con-
servative therapy showed statistically significant effects on 
AsAT and total bilirubin.
Therapy with plasmapheresis showed statistically signif-
icant effects on AsAT, ALT, alkaline phosphatase and total 
bilirubin. Thus, it is the greater the therapy effectiveness 
with the inclusion of plasmapheresis.
To study the prolonged action of plasmapheresis, we 
conducted an analysed repeated referrals of patients. In 
conservative treatment, the average interval between appeals 
was 18 months and 22 months after plasmapheresis therapy.
Table I. Dynamics of homeostasis rates in patients with CH under a conservative treatment and using plasmapheresis.




Total protein, g/l 65-85 76.4±8.8* 72.4±6.1* –
Albumin, % 36-50 43.1±2.5* 42.9±1.0* –
AsAT, O/L 10-30 90.7±20.1* 40.1±15.1* +
ALT, O/L 7-40 76.7±20.2* 40.2±12.0* –
Alkaline phosphatase, O/L 39-117 152.0±19.1* 105.5±20.3* –
Total bilirubin, mcmol/L 3,4-20,5 67.2±10.0* 41.1±8.1* +
Treatment with plasmapheresis
Total protein, g/l 65-85 73.6±5.2* 68.9±5.1* –
Albumin, % 36-50 45.7±2.3* 43.8±3.1* –
AsAT, O/L 10-30 125.6±41.2* 37.1±14.2* +
ALT, O/L 7-40 94.2±23.4* 38.3±15.1* +
Alkaline phosphatase, O/L 39-117 174.9±41.8* 73.1±27,4* +
Total bilirubin, mcmol/L 3,4-20,5 74.1±21.4* 25.5±8.1* +
*the indicator is considered unreliable p<0.05
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As a result of a survey of patients who were discharged 
at the time of publication after an in-hospital treatment, 
the average cost of therapy was 42.5 euros. According to 
a sample retrospective study of a history of 10 years, the 
cost of therapy for 1 patient at treatment every 18 months 
(7 times for 10 years) is 42.5x7 = 297.5 euros.
  The cost of the plasmapheresis procedure on Scinomed 
machine we have taken to calculate is 19 euros (basic fixed 
and variable costs, including staff salaries and utilities ac-
cording Ukrainian law, are also taken into account).
The course of treatment consists of 3 procedures as 
minimum, which require 57 euros. For 10 years the cost 
of treatment with plasmapheresis for 1 patient at treatment 
every 22 months (5 times for 10 years) is 57x5 = 285 euros.
Today the cost of therapy is 297.5 euros, the economic effect 
during 10 years from the implementation of plasmapheresis 
can be estimated at 297.5-285 = 12 euros for each patient.
Therefore, the economic effect for Ukraine can be cal-
culated as follows.
According statistics there are 104879 cases with such 
a pathology are officially registered in Ukraine, then the 
inclusion of plasmapheresis can have an economic effect 
for the year 12x104879 = 209758 euros.
And considering that only 7% of the estimated number 
of patients is recorded, then the possible economic effect 
is: 12x104879x100 / 7 = 2 996 542 euros
These data indicate the need for further more in-depth 
study of ways to optimize the treatment of nosologies, in 
which the effectiveness of plasmapheresis is proven. 
CONCLUSIONS
The absence of a significant and stable effect of the conser-
vative treatment of CH indicates the need to improve the 
quality of a medical care for patients with CH by using more 
effective up-to-date techniques, such as usage of plasma-
pheresis in a complex of therapeutic measures. Inclusion 
plasmapheresis in the complex therapy of CH reduces the 
express of cytolysis and cholestasis, increases remission and 
significantly improves clinical manifestations. Therefore, it 
is relevant to use this technique in clinical practice.
It is determined that the inclusion of therapeutic plas-
mapheresis in the complex therapy of hepatitis leads to an 
economic effect and requires further study of the impact 
of this method with a view to its implementation through 
the use of modern economic and marketing methods 
not only at the state level, but also in the private family 
medicine sector.
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